期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌中Ki67、Her-2和nm23的表达及其临床意义 被引量：5

Expressions and the clinical significances of Ki67,Her-2 and nm23 in breast cancer
暂未订购
导出
摘要 目的研究Ki67、Her-2和nm23蛋白在乳腺癌组织中的表达,探讨其临床意义。方法应用免疫组化方法检测104例乳腺癌组织中Ki67、Her-2和nm23蛋白的表达水平。结果 Ki67、Her-2和nm23蛋白表达与乳腺癌淋巴结转移均密切相关。结论联合检测Ki67、Her-2和nm23蛋白表达是衡量乳腺癌预后的重要指标。 Objective To study the expression of Ki67,Her-2 and nm23 protein in breast cancer,and the relation to biological behavior and prognosis.Methods The expression of Ki67,Her-2 and nm23 protein were determined by immunohistochemistry technique in 104 patients with gastric carcinoma.Results The expression levels of Ki67,HER-2 and nm23 protein were closely correlated with regional lymph node metastasis.Conclusion Combined analysis of Ki67,HER-2 and nm23 protein expression showed that were important indicator for judging the prognosis of breast cancer.
作者 赵鹰 胡长军 王鹏 马斌林 刘虎
机构地区 新疆伊犁州友谊医院普外二科 新疆医科大学附属肿瘤医院
出处 《中国现代药物应用》 2010年第18期18-19,共2页 Chinese Journal of Modern Drug Application
关键词 乳腺癌 KI67 HER-2 NM23基因蛋白 免疫组织化学 Breast cancer Her-2 Ki67 nm23 Immunohistochemistry
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量：1379
  • 2Ramires M.An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffusetype carcinomas.Pathol,1997,182(1):62 -67.
  • 3Sauer T,Beraki K,Jebsen PW,et al.Numerical aberrations of chromosome 17 interphase cill nuclei of breast carcinoma cell:lack of correlation with abnormal expression of p53,neu and nm23 protein.APMIS,2008,106(10):921.
  • 4Mittra I,Redkar AA,Badwe RA.Prognosis of breast cancer evidence for interaction between c-erbB-2 overpression and number of involved axillary lymph nodes.J Surg Oncol,2005,60(2):106.
  • 5王进,马斌林.乳腺癌HER-2基因的表达及其临床意义[J].中国肿瘤临床与康复,2006,13(1):14-16. 被引量：16
  • 6Masood S.Assessment of Her-2/neu overpression in primary breast cancers and their metastatic lesions an inmunohistochemical study.Ann clin lab Sci,2000,10(3):57-75.
  • 7陈军,王懿龄.C-erbB-2、P53n、m23在乳腺癌中表达的临床意义[J].中国实验诊断学,2007,11(1):132-133. 被引量：15
  • 8Sato S,Miyauchi M,Ogawa L,et al.Inhibition of nm23 upregulates the invation ability of oral sqamous cell carcinscells.Oral Oncol,2003,39(1):27-30.
  • 9Goi T Koneri K,Katayama K,et al.Evaluation of clinicopological factors and the correlation between the adhesion mole nm23 expression and pulmonary metasess from colon cancers.Int Surg,2002,87(2):130-136.
  • 10Dall P,Heider KH,Sinn HP,et al.Comparision of immunohis tochemistry and RT-PCR for deletion of nm23 expression:a newprognostic in human breast cancer.Cancer Reserve,2005,70(5):471-476.

二级参考文献19

  • 1赵彤,朱梅刚,黄宗义,张亚历,张素娟,李梅芳.肺癌癌基因蛋白产物同步检测的对比分析[J].癌症,1995,14(1):13-15. 被引量：54
  • 2谷化平,冯和平,徐志勇,苏红.免疫组化在恶性黑色素瘤诊断中的作用[J].中国肿瘤临床,1996,23(8):599-600. 被引量：4
  • 3Emin Y, Tahsin D, Ugh RB. Prognostic significance of young age in breast cancer[J].Surg Oncol,2000 ,74 :267-272.
  • 4Goldenberg MM. Trastzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer[J]. Clin Ther, 1999,21 (2) :309-318.
  • 5Pegram MD,Pauletti G,Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy [J]. Breast Cancer Res Treat, 1998,52(1-3):765-772.
  • 6Geisler S, Lonning P E, Aas T, et al.Influence of Tp53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer[J]. Cancer Res,2001,61 (6):2505-2512.
  • 7Beth S, Best hope or last hope access to phase Ⅲ clinical trials of HER-2/neu for advanced stage breast cancer patients [J]. J Adv Nurs,2000,31 (2) :259-266.
  • 8Hayes DF,Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker [J]. Semin Oncol, 2002,29(3):231 -245.
  • 9Petit T, Borel C, Ghnassia JP,et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting[J]. Clin Cancer Res,2001,7(6) : 1577-1581.
  • 10Slamon DJ,Leyland JB, Shsk S,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001,344(11):783-792.

共引文献1407

同被引文献51

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量：1379
  • 2Mohsin SK,Zhang M,Clark GM,et al.maspin expression in invasive breast cancer:association with other prognostic factors.J Pathol,2003,199:432-435.
  • 3Ji H,Liu YE,Jia T,et al.Identification of a breast cancer specific gene,BCSG1,by direct differential cDNA sequencing.Cancer Res,1997,57:759-764.
  • 4Lavedan C,Leroy E,Dehejia A,et al.Identification,localization,and characterization of the human γ-synuclein gene.Hum Genet,1998,103:106-112.
  • 5Jia T,Liu YE,Liu J,et al.Stimulation of breast cancer invasion and metastasis by synucleingamma.Cancer Res,1999,59:742-747.
  • 6Tan PH,Bay BH,Yip G,et al.Immunohistochemical detection of Ki67 in breast cancer correlates with trance rjptional regulation of genes related to apoptosis and cell death.Mod Pathol,2005,18:374-381.
  • 7Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalizedmedicine[J]. Oncologist,2009,14(4): 320-368.
  • 8Shi YX, Tan YT, Yuan ZY, et al. Comparison of overall survival between the early use and delayed use of trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer[J]. Med Oncol,2012, 29(1) :39-47.
  • 9Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamidetherapy in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubiein (HERCULES) trial[J]. J Clin Oncol,2010,28(9) :1473-1480.
  • 10Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positlve locally advanced breast cancer (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010,375 (9712) : 377-384.

引证文献5

二级引证文献26

中国现代药物应用
2010年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部